Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market
Sunshine Biopharma (NASDAQ:SBFM) has announced the launch of 狈滨翱笔贰骋庐, its first biosimilar drug, through its Canadian subsidiary Nora Pharma. 狈滨翱笔贰骋庐 is comparable to NEULASTA庐 (Pegfilgrastim) and is designed to reduce infection risk in chemotherapy patients with non-myeloid malignancies.
The global market for NEULASTA庐 and its biosimilars was valued at $4.5 billion in 2024, with projections to reach $9.2 billion by 2033, growing at a CAGR of 8.5%. In Canada, where biologic drug sales reached $10 billion in 2020, the market represents a significant opportunity due to high per capita biologics spending and favorable provincial switching policies.
Sunshine Biopharma (NASDAQ:SBFM) ha annunciato il lancio di 狈滨翱笔贰骋庐, il suo primo farmaco biosimilare, tramite la sua controllata canadese Nora Pharma. 狈滨翱笔贰骋庐 猫 comparabile a NEULASTA庐 (Pegfilgrastim) ed 猫 progettato per ridurre il rischio di infezioni nei pazienti sottoposti a chemioterapia con neoplasie non mieloidi.
Il mercato globale di NEULASTA庐 e dei suoi biosimilari 猫 stato valutato 4,5 miliardi di dollari nel 2024, con previsioni di raggiungere 9,2 miliardi di dollari entro il 2033, crescendo a un CAGR dell'8,5%. In Canada, dove le vendite di farmaci biologici hanno raggiunto 10 miliardi di dollari nel 2020, il mercato rappresenta un'opportunit脿 significativa grazie alla spesa pro capite elevata per i biologici e alle politiche provinciali favorevoli al switching.
Sunshine Biopharma (NASDAQ:SBFM) ha anunciado el lanzamiento de 狈滨翱笔贰骋庐, su primer medicamento biosimilar, a trav茅s de su subsidiaria canadiense Nora Pharma. 狈滨翱笔贰骋庐 es comparable a NEULASTA庐 (Pegfilgrastim) y est谩 dise帽ado para reducir el riesgo de infecciones en pacientes con quimioterapia para malignidades no mieloides.
El mercado global de NEULASTA庐 y sus biosimilares fue valorado en 4.5 mil millones de d贸lares en 2024, con proyecciones de alcanzar 9.2 mil millones de d贸lares para 2033, creciendo a una Tasa de Crecimiento Anual Compuesta (CAGR) del 8.5%. En Canad谩, donde las ventas de medicamentos biol贸gicos alcanzaron 10 mil millones de d贸lares en 2020, el mercado representa una oportunidad significativa debido al alto gasto per c谩pita en biol贸gicos y a las pol铆ticas provinciales favorables para el cambio de medicamentos.
Sunshine Biopharma (NASDAQ:SBFM)電� 旌愲倶雼� 鞛愴殞靷� Nora Pharma毳� 韱淀暣 觳� 氚旍澊鞓れ嫓氚�霟� 鞚橃暯頀� 狈滨翱笔贰骋庐鞚� 於滌嫓毳� 氚滍憸頄堨姷雼堧嫟. 狈滨翱笔贰骋庐電� NEULASTA庐(韼橁犯頃勱犯霛检姢韺�)鞕� 鞙犾偓頃橂┌, 牍勱敞靾橃劚 鞎呾劚膦呾枒 頇橃瀽鞚� 頇旐暀鞖旊矔 欷� 臧愳椉 鞙勴棙鞚� 欷勳澊旮� 鞙勴暣 靹り硠霅橃棃鞀惦媹雼�.
NEULASTA庐 氚� 攴� 氚旍澊鞓れ嫓氚�霟潣 旮�搿滊矊 鞁滌灔鞚� 2024雲� 旮办 45鞏� 雼煬搿� 韽夑皜霅橃棃鞙茧┌, 2033雲勱箤歆� 92鞏� 雼煬鞐� 鞚措ゼ 瓴冹溂搿� 鞓堨儊霅橂┌, 鞐绊弶攴� 靹膘灔毳�(CAGR) 8.5%搿� 靹膘灔頃橁碃 鞛堨姷雼堧嫟. 2020雲� 旌愲倶雼れ棎靹� 靸濍頃欖爜 鞝滌牅 毵れ稖鞚� 100鞏� 雼煬鞐� 雼晿電� 臧�鞖措嵃, 1鞚鸽嫻 靸濍頃欖爜 鞝滌牅 歆�於滌澊 雴掙碃 歆�氚� 鞝曤秬鞚� 鞝勴櫂 鞝曥眳鞚� 鞖绊樃鞝侅澊鞏挫劀 鞚� 鞁滌灔鞚� 韥� 旮绊殞毳� 鞝滉车頃╇媹雼�.
Sunshine Biopharma (NASDAQ:SBFM) a annonc茅 le lancement de 狈滨翱笔贰骋庐, son premier m茅dicament biosimilaire, via sa filiale canadienne Nora Pharma. 狈滨翱笔贰骋庐 est comparable 脿 NEULASTA庐 (Pegfilgrastim) et est con莽u pour r茅duire le risque d'infection chez les patients sous chimioth茅rapie atteints de tumeurs non my茅lo茂des.
Le march茅 mondial de NEULASTA庐 et de ses biosimilaires 茅tait 茅valu茅 脿 4,5 milliards de dollars en 2024, avec des projections atteignant 9,2 milliards de dollars d'ici 2033, avec un taux de croissance annuel compos茅 (CAGR) de 8,5%. Au Canada, o霉 les ventes de m茅dicaments biologiques ont atteint 10 milliards de dollars en 2020, ce march茅 repr茅sente une opportunit茅 importante en raison des d茅penses 茅lev茅es par habitant en biologiques et des politiques provinciales favorables au changement de traitement.
Sunshine Biopharma (NASDAQ:SBFM) hat die Markteinf眉hrung von 狈滨翱笔贰骋庐, seinem ersten Biosimilar-Medikament, 眉ber seine kanadische Tochtergesellschaft Nora Pharma bekanntgegeben. 狈滨翱笔贰骋庐 ist vergleichbar mit NEULASTA庐 (Pegfilgrastim) und wurde entwickelt, um das Infektionsrisiko bei Chemotherapiepatienten mit nicht-myeloischen Malignomen zu reduzieren.
Der globale Markt f眉r NEULASTA庐 und dessen Biosimilars wurde im Jahr 2024 auf 4,5 Milliarden US-Dollar gesch盲tzt, mit Prognosen, bis 2033 auf 9,2 Milliarden US-Dollar zu wachsen, bei einer j盲hrlichen Wachstumsrate (CAGR) von 8,5%. In Kanada, wo der Verkauf von Biologika im Jahr 2020 10 Milliarden US-Dollar erreichte, stellt der Markt aufgrund der hohen Pro-Kopf-Ausgaben f眉r Biologika und g眉nstiger provincialer Wechselrichtlinien eine bedeutende Chance dar.
- Entry into the high-value biologics market with 狈滨翱笔贰骋庐 biosimilar
- Target market projected to grow from $4.5B to $9.2B by 2033 (8.5% CAGR)
- Strategic expansion into Canadian market with high per capita biologics spending
- Favorable market conditions due to provincial switching policies encouraging biosimilar adoption
- Entering a competitive market dominated by established NEULASTA庐 brand
- Canadian market represents only a small portion of the global opportunity
Insights
Sunshine Biopharma enters lucrative biosimilars market with 狈滨翱笔贰骋庐, targeting significant revenue in the growing $4.5B Pegfilgrastim segment.
Sunshine Biopharma's launch of 狈滨翱笔贰骋庐 marks their strategic entry into the high-margin biosimilars market. This pegfilgrastim biosimilar addresses a
The company is targeting Canada initially - a smaller but lucrative market where biologics comprise about one-third of pharmaceutical spending (
This launch represents a significant business model evolution for Sunshine Biopharma. By entering the biosimilars space, the company diversifies beyond research-stage assets to include marketed products with immediate revenue potential. Biosimilars typically offer higher margins than traditional generics while requiring less R&D investment than novel drugs.
The pegfilgrastim market is particularly attractive as the drug addresses chemotherapy-induced neutropenia, a side effect experienced by many cancer patients. With increasing cancer incidence driving chemotherapy use, demand for supportive care medications like 狈滨翱笔贰骋庐 should remain robust despite pricing pressures from competing biosimilars.
From a clinical perspective, 狈滨翱笔贰骋庐's introduction provides oncologists with another option for managing chemotherapy-induced neutropenia, a potentially life-threatening condition. Pegfilgrastim biosimilars have demonstrated therapeutic equivalence to the reference product NEULASTA庐 in clinical trials, with comparable safety profiles and efficacy in reducing febrile neutropenia incidence.
The availability of another biosimilar benefits the healthcare system in multiple ways. First, it introduces additional price competition in a category dominated by high-cost biologics. Second, it improves supply chain resilience by diversifying manufacturing sources for this critical supportive care medication.
Pegfilgrastim remains a cornerstone in supportive cancer care because it significantly reduces hospitalization rates due to neutropenic fever. The once-per-chemotherapy-cycle dosing of pegfilgrastim products like 狈滨翱笔贰骋庐 improves patient compliance compared to daily injections required with short-acting filgrastim.
The prefilled syringe formulation (6mg/0.6mL) mentioned in the release is the standard delivery method, though the announcement doesn't specify whether 狈滨翱笔贰骋庐 will also be available in on-body injector formats similar to NEULASTA庐 Onpro庐, which can further improve the patient experience by eliminating return visits solely for injection administration.
FORT LAUDERDALE, FL / / July 2, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched 狈滨翱笔贰骋庐, the Company's first Biosimilar drug on the market.
狈滨翱笔贰骋庐 is a Biosimilar comparable to the reference biologic drug NEULASTA庐 (Pegfilgrastim). Like NEULASTA庐, 狈滨翱笔贰骋庐 is a long-acting, pegylated form of recombinant human granulocyte colony-stimulating factor (filgrastim). It is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving chemotherapy. 狈滨翱笔贰骋庐 is available in a prefilled syringe of 6mg/0.6mL.
As of 2024, the global market size for NEULASTA庐 and its biosimilars was estimated at
The Canadian market for NEULASTA庐 and its Biosimilars is smaller but still significant due to high biologics spending. Biologic drug sales in Canada reached
Although Canada represents a smaller slice of the global market, its per capita biologics spending ranks among the highest in the OECD (Organisation for Economic Co-operation and Development), making it a valuable market for both branded and biosimilar products.
"The launch of 狈滨翱笔贰骋庐 as a biosimilar to NEULASTA庐 represents a strategic milestone in our growth trajectory," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. By entering the high value-added biologics market with a cost-effective and clinically equivalent alternative, we are strengthening our portfolio, expanding our addressable market, and creating new revenue streams. This reinforces our commitment to delivering sustainable value to patients, the healthcare system, and our shareholders alike."
About Sunshine Biopharma Inc.
Sunshine Biopharma currently has 72 generic prescription drugs on the market in Canada and more than 12 additional drugs planned to be launched in the remainder of 2025. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: .
All registered trademarks are the property of their respective owners.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
For more information, please contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
[email protected]
SOURCE: Sunshine Biopharma Inc.
View the original on ACCESS Newswire
FAQ
What is Sunshine Biopharma's (SBFM) 狈滨翱笔贰骋庐 and what is it used for?
How big is the market opportunity for SBFM's 狈滨翱笔贰骋庐?
What is the size of the Canadian biologics market where 狈滨翱笔贰骋庐 launched?
How does 狈滨翱笔贰骋庐 fit into Sunshine Biopharma's business strategy?
What are the growth drivers for NIOPEG's target market?
